Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma

http://ir.exelixis.com/phoenix.zhtml?c=120923&p=irol-newsArticle&ID=2383313

BEGIN Berkeley Gateway to Innovation
portal to the UC Berkeley entrepreneurship community

Join the IPIRA Mailing List

Read the IPIRA Newsletter

Accessibility | Nondiscrimination | Privacy

© 2022 Regents of the University of California. All Rights Reserved.